

### 3.1 患者背景一覧表

#### 3.1.1 患者背景一覧

患者背景		血縁者間 骨髄移植	血縁者間末梢血 幹細胞移植	非血縁者間 骨髄移植	臍帯血移植	合計
患者数		1032	1078	2232	1603	5945
性別	男	577 (55.9%)	614 (57.0%)	1355 (60.7%)	940 (58.6%)	3486 (58.6%)
	女	455 (44.1%)	464 (43.0%)	876 (39.3%)	662 (41.3%)	2457 (41.3%)
	不明・未記載	0 (0.0%)	0 (0.0%)	1 (0.0%)	1 (0.1%)	2 (0.1%)
年齢	0-17	325 (31.5%)	97 (9.0%)	334 (15.0%)	296 (18.5%)	1052 (17.7%)
	18-55	559 (54.2%)	718 (66.6%)	1411 (6.2%)	856 (53.4%)	3544 (59.6%)
	56-	148 (14.3%)	262 (24.3%)	487 (21.8%)	450 (28.1%)	1347 (22.7%)
	不明・未記載	0 (0.0%)	1 (0.1%)	0 (0.0%)	1 (0.1%)	2 (0.0%)
診断	AML	308 (29.8%)	398 (36.9%)	822 (36.8%)	734 (45.8%)	2262 (38.1%)
	ALL	256 (24.8%)	187 (17.4%)	446 (20.0%)	300 (18.7%)	1189 (20.0%)
	ATL	31 (3.0%)	62 (5.8%)	109 (4.9%)	45 (2.8%)	247 (4.2%)
	CML	24 (2.3%)	32 (3.0%)	69 (3.0%)	43 (2.7%)	168 (2.8%)
	MDS	90 (8.7%)	93 (8.6%)	237 (10.6%)	129 (8.1%)	549 (9.2%)
	NHL	72 (7.0%)	151 (14.0%)	235 (10.5%)	159 (9.9%)	617 (10.4%)
	固形腫瘍	23 (2.2%)	16 (1.5%)	6 (0.3%)	27 (1.7%)	72 (1.2%)
	その他	228 (22.2%)	139 (12.9%)	308 (13.8%)	166 (10.4%)	841 (14.4%)
移植時病期	CR	430 (41.9%)	379 (35.5%)	1068 (47.9%)	535 (33.6%)	2412 (40.8%)
	Non-CR	295 (28.7%)	513 (48.1%)	737 (33.1%)	779 (48.9%)	2324 (39.3%)
	その他	236 (23.0%)	108 (10.1%)	316 (14.2%)	158 (9.9%)	818 (13.8%)
	不明・未記載	66 (6.4%)	67 (6.3%)	107 (4.8%)	121 (7.6%)	361 (6.1%)
BU剤型	BU (経静脈)を含むレジメン	209 (87.1%)	293 (71.3%)	545 (77.3%)	236 (78.9%)	1283 (77.5%)
	BU (経口)を含むレジメン	31 (12.9%)	118 (28.7%)	160 (22.7%)	63 (21.1%)	372 (22.5%)
前治療レジメン	BU (経静脈)+CY±other	101 (15.2%)	95 (15.4%)	216 (12.6%)	53 (4.4%)	465 (11.1%)
	CY+TBI±other	335 (50.5%)	271 (43.8%)	835 (48.8%)	486 (40.3%)	1927 (45.9%)
	BU (経静脈)+FL±other	86 (13.0%)	169 (27.3%)	304 (17.8%)	164 (13.6%)	723 (17.2%)
	FL+TBI±other	142 (2.4%)	84 (13.6%)	357 (20.9%)	502 (41.7%)	1085 (25.8%)
GVHD予防薬	MTX+CyA	565 (54.8%)	538 (49.9%)	420 (18.8%)	478 (29.8%)	2001 (33.7%)
	MTX+FK506	296 (28.7%)	211 (19.6%)	1685 (75.5%)	437 (27.3%)	2629 (44.2%)
	その他	171 (16.5%)	329 (30.5%)	127 (5.7%)	822 (42.9%)	1315 (22.1%)

略語	
BU	Busulfan
CY	Cyclophosphamide
TBI	Total body irradiation
FL	Fludarabine phosphate